ANI Pharmaceuticals Inc (ANIP) was Downgraded by Standpoint Research to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Standpoint Research advised their investors in a research report released on May 24, 2016.
On the company’s financial health, ANI Pharmaceuticals Inc reported $0.76 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.70. The company had revenue of $20.60 million for the quarter, compared to analysts expectations of $20.84 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.57 EPS.
ANI Pharmaceuticals Inc opened for trading at $47.98 and hit $49.94 on the upside on Friday, eventually ending the session at $49.54, with a gain of 3.88% or 1.85 points. The heightened volatility saw the trading volume jump to 1,51,192 shares. Company has a market cap of $569,363 M.
In a different news, on Dec 22, 2015, James G. Marken (Vice President, Operations) sold 3,500 shares at $43.26 per share price. According to the SEC, on Nov 12, 2015, Arthur Przybyl (CEO) purchased 2,500 shares at $40.95 per share price. On Mar 16, 2015, Tracy Marshbanks (director) sold 210,000 shares at $63.00 per share price, according to the Form-4 filing with the securities and exchange commission.
ANI Pharmaceuticals Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include narcotics oncolytics (anti-cancers) hormones and steroids and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette Minnesota that are capable of producing oral solid dose products as well as liquids and topicals narcotics and potent products. The Company’s branded products consist of Cortenema Lithobid Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone Fluvoxamine Maleate Hydrocortisone Enema Methazolamide Metoclopramide and Opium Tincture. The Company’s markets include hormone and steroidal drugs oncolytics and narcotics and complex formulations including extended release and combination products.